Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Equillium's Pre-Tax Income for the
three
months ended in Dec. 2024 was $-5.43 Mil. Equillium's Revenue for the
three
months ended in Dec. 2024 was $4.39 Mil. Therefore, Equillium's pretax margin for the quarter that ended in Dec. 2024 was -123.70%.
The historical rank and industry rank for Equillium's Pretax Margin % or its related term are showing as below:
EQ'
s Pretax Margin % Range Over the Past 10 Years
Min: -396.14 Med: -35.35 Max: -18.75
Current: -18.75
EQ's Pretax Margin % is ranked better than 66.87% of 999
companies
in the Biotechnology industry
Industry Median: -136.49
vs EQ: -18.75
Equillium Pretax Margin % Historical Data
The historical data trend for Equillium's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Equillium's Pretax Margin %
For the Biotechnology subindustry, Equillium's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Equillium's Pretax Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Equillium's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Equillium's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equillium (NAS:EQ) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Equillium Pretax Margin % Related Terms
Thank you for viewing the detailed overview of Equillium's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EQ has been successfully added to your 